A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis

Trial Profile

A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs AN 2898 (Primary) ; Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Anacor Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2014 New trial record
    • 27 Feb 2014 Anacor Pharmaceuticals originally reported the results of this study on 12 December 2011, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top